Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals

Kobal, Borut; Noventa, Marco; Cvjetičanin, Branko; Barbič, Matija; Meglič, Leon; Herzog, Maruša; Bordi, Giulia; Vitagliano, Amerigo; Saccardi, Carlo; Škof, Erik

doi:10.2478/raon-2018-0030

Cited by 48 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, generation of the CP70 drug resistant cell line closely mimics clinical patient treatment protocols. While this approach is necessary, clinical trials have repeatedly demonstrated that shortening the period of time between chemotherapy infusions provides a survival advantage [84, 85]. Moreover, recurrent disease is more prevalent in patients that are neo-adjuvant treated as opposed to those that receive up-front surgical de-bulking [86].…”

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance

Kovács

Vermeer

Madeo

et al. 2020

Preprint

View full text Add to dashboard Cite

Patients with densely innervated tumors do poorly as compared to those with sparsely innervated disease. Why some tumors heavily recruit nerves while others do not, remains unknown as does the functional contribution of tumor-infiltrating nerves to cancer. Moreover, while patients receive chemotherapeutic treatment, whether these drugs affect nerve recruitment has not been tested. Using a murine model of ovarian cancer, we show that tumor-infiltrating sensory nerves potentiate tumor growth, decrease survival, and contribute to treatment resistance. Furthermore, matched patient samples show significantly increased tumor innervation following chemotherapy. In vitro analysis of tumor-released extracellular vesicles (sEVs) shows they harbor neurite outgrowth activity. These data suggest that chemotherapy may alter sEV cargo, endowing it with robust nerve recruiting capacity.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance

Kovács

Vermeer

Madeo

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Most of the patient will relapse within 24 months of the treatment, which has unfortunately been unchanged in recent decades despite developments in chemo pharmacy. 2 Predicting risk of recurrence will allow patients to have a better quality of life and clinicians to better approach in ovarian cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

Jakimovska

Černe

Verdenik

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Role of soluble vascular cell adhesion molecule-1 (sVCAM-1) in ovarian cancer is largely unclear. It was shown that mesothelial expression mediates tumour cell invasion and is associated with metastases in advanced ovarian cancer.Results: Mean sVCAM-1 serum concentration in all patients before operation was 1564.68 ± 435.65 ng/ml while mean ascites level was 801.84 ±244.35 ng/ml. Follow up period was minimum 27 and the maximum 58 months. Patients were divided in two groups according to time to recurrence. Group A: 20 patients with disease progress or relapse within 12 months (mean serum level 1660.54±417.93 ng/ml; mean ascites level 827.92±290.36) and group B: 17 patients with tumour relapse after more than 12 months (mean serum level 451.91±441.15ng/ml; mean ascites level 771.16±179.93). There was statistically significant difference in serum concentration and not in ascites concentrations of sVCAM-1, grade, histology and stage and tumour between the groups. There was a correlation between serum and ascites concentrations in group A and not in the patients from group B. Increased sVCAM-1 concentration in serum and ascites relates to advance ovarian cancer.Conclusions: This is the first study demonstrating that higher serum sVCAM-1 concentrations at the time of diagnosis might be predictive for early relapse. Serum sVCAM-1 can be potential marker for ovarian cancer follow-up.

show abstract

“…1 Most of the patient will relapse within 24 months of the treatment, which has unfortunately been unchanged in recent decades despite developments in chemo pharmacy. 2 Predicting risk of recurrence will allow patients to have a better quality of life and clinicians to better approach in ovarian cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

Jakimovska

Černe

Verdenik

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Role of soluble vascular cell adhesion molecule-1 (sVCAM-1) in ovarian cancer is largely unclear. It was shown that mesothelial expression mediates tumour cell invasion and is associated with metastases in advanced ovarian cancer. Material and methods: In our prospective study we measured preoperative serum sVCAM-1 in 37 patients with advanced ovarian cancer and evaluated correlation with disease recurrence. Serum samples were obtained prior to surgery, ascites was collected during the surgery and all analysed by flow cytometric bead-based assay. ROC analysis was used to identify a cut-off value for sVCAM-1. Survival curves were calculated using Kaplan-Meier method. The association between sVCAM-1 and survival was investigated with Cox regression models, adjusting for age at surgery. A p of <0.05 was considered significant. Results: Mean sVCAM-1 serum concentration in all patients before operation was 1564.68 ± 435.65 ng/ml while mean ascites level was 801.84 ±244.35 ng/ml. Follow up period was minimum 27 and the maximum 58 months. Patients were divided in two groups according to time to recurrence. Group A: 20 patients with disease progress or relapse within 12 months (mean serum level 1660.54±417.93 ng/ml; mean ascites level 827.92±290.36) and group B: 17 patients with tumour relapse after more than 12 months (mean serum level 451.91±441.15ng/ml; mean ascites level 771.16±179.93). There was a correlation between serum and ascites concentrations in group A and not in the patients from group B. The statistically significant difference was observed in serum concentration but not in ascites concentrations of sVCAM-1, There were no differences in grade, histology and stage of the tumour between the groups. sVCAM-1 and age resulted correlated (Spearman r=0.32, p=0.048). In Cox regression models after adjusting for age at surgery, sVCAM-1 above 1,400 ng/ml was associated with impaired DFS (hazard ratio 3.824; 95% confidence interval 1.460 to 9.374; p=0.003) and impaired OS (hazard ratio 13.394; 95% confidence interval 1.693 to 105.3985; p=0.014. Conclusions: This is the first study demonstrating that higher serum sVCAM-1 concentrations at the time of diagnosis might be predictive for early relapse. Serum sVCAM-1 can be potential marker for ovarian cancer follow-up.

show abstract

Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals

Cited by 48 publications

References 33 publications

Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance

Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

High Preoperative Serum sVCAM-1 Concentration as a Predictor of Early Ovarian Cancer Recurrence

Contact Info

Product

Resources

About